| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C106H216N10O10 |
| Purity | |
| SMILES | |
| Form | Oil |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
G0-C14 is a cationic, lipid-like alkyl-modified polyamidoamine (PAMAM) dendrimer used in the preparation of macrophage-targeted nanoparticles (NPs), which can be applied for agent and vaccine delivery[1][2]. It is supplied as a colorless to light yellow oil (C106H216N10O10, MW 1790.91) at 98.0% purity.
Physical & Chemical Properties
| CAS Number | 1510653-27-6 |
|---|---|
| Molecular Formula | C106H216N10O10 |
| Molecular Weight | 1790.91 g/mol |
| Purity | 98.0% |
| Appearance | Oil |
| Color | Colorless to light yellow |
| SMILES | O=C(CCN(CCN(CCC(NCCN(CC(CCCCCCCCCCCC)O)CC(CCCCCCCCCCCC)O)=O)CCC(NCCNCC(CCCCCCCCCCCC)O)=O)CCC(NCCN(CC(CCCCCCCCCCCC)O)CC(CCCCCCCCCCCC)O)=O)NCCNCC(CCCCCCCCCCCC)O |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: 100 mg/mL (55.84 mM; Requires sonication and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Pure form: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (55.84 mM) | requires sonication and warming and heat to 80°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | 2.5 mg/mL (1.40 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 2.5 mg/mL (1.40 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | 2.5 mg/mL (1.40 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
G0-C14 entraps mRNA and pDNA strongly, as shown by an encapsulation efficiency above 95%[1]. NP preparation[1]: 1. Dissolve PolyHCPT and DSPE-PEG3K in DMF to give a homogeneous solution at a concentration of 5 mg/mL. 2. Combine 1 nmol of siRNA (as 0.1 nmol/μL aqueous solution) with G0-C14 (5 mg/mL in DMF) at different N/P molar ratios, then mix it with the PolyHCPT and DSPE-PEG3K solution. 3. Add the mixture dropwise to 5 mL of deionized water under vigorous stirring (1000 rpm). 4. Transfer the resulting NP dispersion to an ultrafiltration device. 5. Centrifuge (2800 rpm×8 min) at room temperature to eliminate the organic solvent and free compounds.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Structure-Activity Mapping of Intraperitoneal mRNA-LNPs: Decoupling Tumor and Liver Biodistribution in Pancreatic Cancer. bioRxiv 2026 Mar 21:2026.03.20.712457. PMID: 41889911
Patent. US20250161481A1.
